Eli Lilly (LLY) Gross Margin (2009 - 2026)

Eli Lilly has reported Gross Margin for 18 years, with the latest figure at 81.93% in Q1 2026.

• For the quarter ending Q1 2026, Gross Margin fell 59.0% year-over-year to 81.93%; the trailing twelve-month figure through Mar 2026 stood at 82.83% (up 113.0% YoY), and the FY2025 full-year result was 83.04%, up 173.0% from the prior year.
• Gross Margin for Q1 2026 stood at 81.93%, down from 82.52% in the prior quarter.
• The five-year high for Gross Margin was 84.27% in Q2 2025, with the low at 73.47% in Q1 2022.
• Historically, Gross Margin has averaged 80.16% across 5 years, with a median of 80.89% in 2023.
• The largest YoY upside for Gross Margin was 693 bps in 2022 against a maximum downside of 162 bps in 2022.
• Eli Lilly's Gross Margin stood at 78.8% in 2022, then advanced by 3 bps to 80.89% in 2023, then gained by 2 bps to 82.24% in 2024, then gained by 0 bps to 82.52% in 2025, then decreased by 1 bps to 81.93% in 2026.
• The last three Gross Margin figures came in at 81.93% (Q1 2026), 82.52% (Q4 2025), and 82.91% (Q3 2025), per Business Quant data.